Huntington's Disease: The Genetic Countdown and What Research Offers

A 50% Inheritance Risk: The Most Predictable Genetic Tragedy in Neurology

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder in which every child of an affected parent has a 50% probability of inheriting the disease-causing mutation — and everyone who inherits the mutation will develop the disease if they live long enough. This determinism distinguishes HD from most genetic diseases, where penetrance is incomplete or modifier genes create variability. Approximately 30,000 Americans currently have Huntington's disease, and another 200,000 are at risk due to a parent's diagnosis. The disease typically manifests between ages 30 and 50, meaning individuals at risk spend decades knowing they may carry a fatal genetic sentence while remaining clinically normal. Genetic testing is available and definitive — but choosing whether to know is among the most profound personal decisions any individual will face.

The CAG Repeat: A Stuttering Genetic Code

Huntington's disease is caused by an expansion of a CAG trinucleotide repeat in the HTT gene on chromosome 4, which encodes the huntingtin protein. The normal HTT gene contains 10–35 CAG repeats. A repeat length of 36 or more is pathogenic, producing an abnormally long polyglutamine (polyQ) tract in the huntingtin protein. This expanded polyQ region causes the protein to misfold, aggregate, and accumulate in neurons — particularly medium spiny neurons of the striatum — leading to progressive neuronal death.

Anticipation: When the Disease Arrives Earlier Each Generation

Anticipation is the phenomenon by which CAG repeat length tends to expand during transmission from parent to child — particularly during paternal transmission. An affected father with 42 CAG repeats may pass 50 repeats to a child, who will develop the disease at a younger age and with more severe symptoms. This explains the observation of juvenile HD (onset before age 20) in children of affected fathers with large repeat expansions. Maternal transmission also produces expansion but typically with smaller increases per generation. The anticipation mechanism is unique to triplet repeat diseases and makes HD a condition that, in some families, becomes progressively more devastating across generations.

Disease Phases: From Prodrome to Advanced HD

The total disease duration from motor onset to death averages 15–20 years. Chorea — the characteristic, dance-like involuntary movements — is prominent early but often lessens as bradykinesia and rigidity dominate in later stages. The psychiatric manifestations precede motor onset and persist throughout, often causing more functional impairment than the movement disorder.

CAG Length and Age of Onset: A Probabilistic Relationship

CAG repeat length explains approximately 60–70% of the variance in age of onset. The inverse relationship is clear: longer repeats predict earlier onset. A person with 40 repeats might not develop motor symptoms until their 70s; a person with 55 repeats may develop symptoms in their 30s. However, the remaining 30–40% of onset variance is governed by modifier genes and environmental factors not yet fully characterized — which means that individuals with the same repeat length can have onset ages varying by 10–15 years. Genetic counselors use statistical models to provide risk estimates but cannot predict individual onset with precision. The uncertainty is real and irreducible.

Assessment and Monitoring: UHDRS

The Unified Huntington's Disease Rating Scale (UHDRS) is the primary clinical assessment tool for HD, measuring motor function, cognitive performance, behavioral symptoms, and functional capacity on standardized subscales. The UHDRS Total Motor Score (TMS) is the most widely used primary endpoint in clinical trials. The Total Functional Capacity (TFC) scale rates independence across five domains (occupation, finances, domestic chores, personal care, and care level), scoring from 0 (completely dependent) to 13 (fully independent). TFC decline is the strongest predictor of significant care transitions.

Tetrabenazine: Managing Chorea

Tetrabenazine (Xenazine), FDA-approved in 2008 as the first drug specifically approved for HD chorea, depletes presynaptic dopamine by inhibiting the vesicular monoamine transporter 2 (VMAT2). It reduces chorea on the UHDRS TMS but carries significant psychiatric risks — depression, suicidality, sedation, and parkinsonism — that limit its use in patients with concurrent depression or low energy. Deutetrabenazine (Austedo) and valbenazine (Ingrezza), newer VMAT2 inhibitors with improved pharmacokinetic profiles, are also FDA-approved for chorea and have better tolerability in some patients. None of these drugs slow disease progression. They manage the symptoms.

Antisense Oligonucleotide Trials: Promise, Failure, and Ongoing Hope

The most anticipated HD therapeutic strategy is lowering huntingtin protein using antisense oligonucleotides (ASOs) — synthetic RNA-targeting molecules that cause selective degradation of HTT mRNA, reducing production of the toxic protein. Wave Life Sciences conducted two trials of allele-selective ASOs (WVE-120101 and WVE-120102) targeting single-nucleotide polymorphisms associated with the mutant allele; both trials were terminated in 2021 after interim analyses showed no reduction in mutant huntingtin in CSF.

Roche/Genentech's tominersen — the most prominent HD ASO — reduced total huntingtin in CSF by up to 60% in Phase 2. However, the Phase 3 GENERATION HD1 trial was halted in 2021 when interim analysis showed that higher-dose tominersen was associated with worse outcomes than placebo, potentially from reduction of wild-type huntingtin (the normal protein) along with the mutant form. Lower doses and less frequent dosing are being studied in the GENERATION HD2 trial. The mechanism is validated; the dosing and selectivity questions are not yet resolved. The setback was significant but not terminal for the approach.

Genetic Testing: The Ethical Dimensions

Predictive genetic testing for HD is available with essentially 100% diagnostic certainty — a rare situation in medicine. The decision to test is not primarily medical; it is personal. International guidelines from the International Huntington Association recommend predictive testing only for adults (18+), with comprehensive pre-test genetic counseling, psychological support, and follow-up regardless of result. Testing of minors is generally not recommended because it denies the child the choice of not knowing.

Approximately 10–20% of people at risk choose to be tested. The majority choose not to — either because they cannot manage the certainty of a positive result, or because they function better with uncertainty than with confirmed knowledge. Neither choice is wrong. Cascade testing of relatives after a new diagnosis, preimplantation genetic diagnosis (PGD) for prospective parents, and research biobanking are all components of a complete approach to HD genetic counseling. The genetic truth is available. Whether to access it is a deeply human question.